Hematotoxicity after Radioligand Therapy with 177Lu-PSMA-617 in Patients with Metastastic Prostate Cancer

被引：0
作者：
Groener, Daniel [1 ]
Baumgarten, Justus [1 ]
Davis, Karen [1 ]
Happel, Christian [1 ]
Ngoc, Christina Nguyen [1 ]
Wichert, Jennifer [1 ]
Mader, Nicolai [1 ]
Mandel, Philipp [2 ]
Nikolaos, Tselis [3 ]
Gruenwald, Frank [1 ]
Sabet, Amir [1 ]
机构：
[1] Univ Hosp Frankfurt, Nucl Med, Frankfurt, Germany
[2] Univ Hosp Frankfurt, Urol, Frankfurt, Germany
[3] Univ Hosp Frankfurt, Radiat Oncol, Frankfurt, Germany
来源：
JOURNAL OF NUCLEAR MEDICINE | 2020年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
594
引用
收藏
页数：1
相关论文
共 50 条
[31]   177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients with a single functioning kidney [J].
Zhang, Jingjing ;
Kulkarni, Harshad ;
Singh, Aviral ;
Schuchardt, Christiane ;
Niepsch, Karin ;
Langbein, Thomas ;
Baum, Richard .
JOURNAL OF NUCLEAR MEDICINE, 2019, 60
[32]   Management of Dry Eye Toxicity After Treatment With 177Lu-PSMA-617 Radioligand Therapy [J].
Pepin, Abigail ;
Lee, Vivian ;
O'Brien, Sophia ;
Mulugeta, Philipose ;
Taunk, Neil K. .
PRACTICAL RADIATION ONCOLOGY, 2024, 14 (04) :301-304
[33]   Predictors of better response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617 [J].
Ferdinandus, Justin ;
Eppard, Elisabeth ;
Kuerpig, Stefan ;
Gaertner, Florian ;
Fimmers, Rolf ;
Hauser, Stefan ;
Essler, Markus ;
Ahmadzadehfar, Hojjat .
JOURNAL OF NUCLEAR MEDICINE, 2016, 57
[34]   Radioligand therapy with 177Lu-PSMA-617 of metastatic prostate cancer has already been arrived in clinical use [J].
Ahmadzadehfar, Hojjat ;
Essler, Markus ;
Schaefers, Michael ;
Rahbar, Kambiz .
NUCLEAR MEDICINE AND BIOLOGY, 2016, 43 (12) :835-835
[35]   Re-Rechallenge 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer [J].
Aggarwal, Piyush ;
Gunasekaran, Vinisha ;
Sood, Ashwani ;
Kumar, Narendra ;
Rathore, Yogesh ;
Kumar, Rajender ;
Mittal, Bhagwant Rai .
CLINICAL NUCLEAR MEDICINE, 2025, 50 (03) :231-233
[36]   Predictors of better response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617 [J].
Ferdinandus, J. ;
Eppard, E. ;
Kuerpig, S. ;
Gaertner, F. ;
Fimmers, R. ;
Yordanova, A. ;
Hauser, S. ;
Essler, M. ;
Feldmann, G. ;
Ahmadzadehfar, H. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 :S212-S213
[37]   Successful Treatment of Hepatic Metastases of Hormone Refractory Prostate Cancer Using Radioligand Therapy With 177Lu-PSMA-617 [J].
Wei, Xiao ;
Schlenkhoff, Carl ;
Sopora, Claudia ;
Essler, Markus ;
Ahmadzadehfar, Hojjat .
CLINICAL NUCLEAR MEDICINE, 2016, 41 (11) :894-+
[38]   Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride [J].
Ahmadzadehfar, Hojjat ;
Zimbelmann, Stefanie ;
Yordanova, Anna ;
Fimmers, Rolf ;
Kuerpig, Stefan ;
Eppard, Elisabeth ;
Gaertner, Florian C. ;
Wei, Xiao ;
Hauser, Stefan ;
Essler, Markus .
ONCOTARGET, 2017, 8 (33) :55567-55574
[39]   First Experience With 177Lu-PSMA-617 Therapy for Advanced Prostate Cancer in the Netherlands [J].
van Kalmthout, Ludwike ;
Braat, Arthur ;
Lam, Marnix ;
van Leeuwaarde, Rachel ;
Krijger, Gerard ;
Ververs, Tessa ;
Mehra, Niven ;
Bins, Adriaan ;
Hunting, Jarmo ;
de Keizer, Bart .
CLINICAL NUCLEAR MEDICINE, 2019, 44 (06) :446-451
[40]   177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response Reply [J].
Yadav, Madhav Prasad ;
Ballal, Sanjana ;
Tripathi, Madhavi ;
Bal, Chandrasekhal .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (01) :168-169
12345